Endoscopic Ultrasound Radiofrequency Ablation for GISTs

Last updated: September 26, 2023
Sponsor: Instituto Ecuatoriano de Enfermedades Digestivas
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gastrointestinal Diseases And Disorders

Digestive System Neoplasms

Abdominal Cancer

Treatment

Endoscopic ultrasound guided radiofrequency ablation

Clinical Study ID

NCT05453292
IECED-05072022
  • Ages 18-89
  • All Genders

Study Summary

Nowadays, for the selection of the treatment for gastrointestinal stromal tumors (GISTs), tumor size, prognosis, resectability and stage should be considered. Due to mutations in KIT and platelet-derived growth factor alpha (PDGFRA) in 90% of patients with this mesenchymal tumor, many tyrosine kinase inhibitors are used. On the other hand, a resectable tumor is approached by surgery, endoscopic and ablation therapy.

Radiofrequency ablation (RFA) approach has been studied in hepatic GISTs, and hepatic metastases, but its evaluation in esophageal, gastric, and intestinal GISTs is scarce. This study aims to determine the feasibility, safety and efficacy of endoscopic ultrasound (EUS) guided RFA using the 19 G RFA probe developed by Taewong Medical for the treatment of GISTs.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults (> 18 years of age)
  • Confirmed resectable GISTs lesions in esophagus, stomach, and intestine (between 2<5cm or 5-10cm and <5mitotes/HPF)
  • Non-amenable to surgery
  • written informed consent
  • No evidence of metastatic disease on imaging of the chest abdomen and pelvis contrastenhanced computed tomography (CE-CT) or limited liver metastatic disease (maximum 5lesions <= 3 cm)
  • Adequate renal, hepatic, and hematological function

Exclusion

Exclusion Criteria:

  • Pregnancy
  • Rectal GISTs
  • Altered renal, hepatic, or hematological function
  • Inability to provide informed consent
  • Patients with cardiac pacemakers or other implanted electronic devices and/orelectrodes
  • Patients that have right-to-left shunts, severe pulmonary hypertension (pulmonaryartery pressure >90 mmHg), uncontrolled systemic hypertension, and in patients withadult respiratory distress syndrome or any condition that contraindicates theprocedure
  • Inability to tolerate general anesthesia.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Endoscopic ultrasound guided radiofrequency ablation
Phase:
Study Start date:
January 15, 2024
Estimated Completion Date:
September 15, 2024

Study Description

Gastrointestinal stromal tumors (GISTs) are the most common malignant mesenchymal tumors of the gastrointestinal tract. GISTs usually appear like subepithelial lesions covered by normal mucosa, arising from the second of fourth layer of the gastrointestinal tract wall. They are variable in size and mostly asymptomatic, but they can present different clinical behavior as bleeding, pain, or obstruction. The tumor size, location and mitotic rate are important prognostic factors. For resectable tumors >2 cm, surgery is the treatment of choice; the management of tumors <2 cm remains debatable because they present unclear clinical significance and low risk of malignancy. Endoscopic treatment, when complete resection it's possible, could be an option to full thickness laparoscopic resection. Moreover, around 90% of GISTs harbour driver mutation in KIT and platelet-derived growth factor alpha (PDGFRA), making the treatment with tyrosine kinase inhibitors (i.e., imatinib, sunitinib and regorafenib) a suitable option for locally advanced and metastatic disease. Nevertheless, the role of local treatment in advanced and metastatic disease is limited, with few retrospective studies suggesting tumor ablation as a therapeutic approach.

According to literature, thermal ablation has been successfully used for local treatment of hepatic metastases from GISTs (as a curative treatment). However, its feasibility and technical success as a local treatment in esophageal, gastric or intestinal GISTs has not been evaluated.

The investigators aimed to determine the feasibility and efficacy of the RFA electrode developed by Taewong Medical for the treatment of resectable GISTs (esophageal, gastric and intestinal lesions) as well as its limited liver metastases in naïve patients or patients with stable disease following systemic therapy with tyrosine kinase inhibitors. The challenge is whether to introduce local ablative therapy as curative or as part of multimodal treatment in patients with GISTs to obtain a curable disease and an increase in overall survival for metastatic patients.

Connect with a study center

  • Instituto Ecuatoriano de Enfermedades Digestivas (IECED)

    Guayaquil, Guayas 090505
    Ecuador

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.